C4 Therapeutics is a technology company.
C4 Therapeutics has raised $73.0M across 1 funding round.
C4 Therapeutics has raised $73.0M in total across 1 funding round.
C4 Therapeutics has raised $73.0M in total across 1 funding round.
C4 Therapeutics's investors include Cobro Ventures.
C4 Therapeutics is a biotechnology company focused on developing a new generation of medicines through targeted protein degradation (TPD). Their proprietary technology enables the design of molecular degraders, including MonoDAC® (molecular glues) and BiDAC™ (heterobifunctional degraders), to selectively degrade disease-causing proteins. Primarily serving oncology patients, C4 Therapeutics aims to address cancers with unmet medical needs by targeting proteins genetically linked to disease, offering potential advantages over traditional inhibitors. Their approach is strategic, emphasizing targets with clear genetic links, clinical trial feasibility, and biomarker-driven patient selection, positioning them for impactful therapeutic advances and growth in precision oncology[1][2].
C4 Therapeutics was founded by scientists and industry leaders with expertise in protein degradation and drug discovery, though specific founder details are not provided in the available sources. The company emerged from advances in the understanding of targeted protein degradation as a novel therapeutic modality, leveraging proprietary tools like the Cereblon Toolkit to expand the scope of druggable targets. Early traction has been driven by their focus on oncology targets with strong genetic and clinical rationale, enabling them to build a pipeline with promising clinical development pathways[1][2].
C4 Therapeutics operates at the forefront of the targeted protein degradation trend, a transformative approach in drug discovery that shifts from inhibition to selective protein elimination. This timing is critical as the pharmaceutical industry seeks novel modalities to tackle diseases with limited treatment options, especially in oncology. Market forces favor companies that can deliver precision therapies with biomarker-driven patient selection, and C4’s platform aligns with this shift. Their work influences the broader biotech ecosystem by validating TPD as a viable therapeutic strategy and expanding the druggable proteome, potentially accelerating innovation across multiple disease areas[1][2].
Looking ahead, C4 Therapeutics is poised to advance its pipeline through clinical trials, potentially bringing first-in-class TPD therapies to market. Trends shaping their journey include increasing acceptance of protein degradation in drug development, advances in biomarker technologies, and growing demand for precision oncology treatments. Their influence may expand beyond oncology as their platform adapts to other disease areas. Continued innovation and successful clinical outcomes will be key to solidifying their role as a leader in next-generation medicine, transforming how diseases are treated by targeting proteins for degradation rather than inhibition[1][2].
C4 Therapeutics has raised $73.0M across 1 funding round. Most recently, it raised $73.0M Series A in January 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2016 | $73.0M Series A | Cobro Ventures |